https://www.live-feeds.com/feed/bristol-myers-ends-deal-with-cellares-cell-therapy-manufacturer-to-reorgContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/bristol-myers-ends-deal-with-cellares-cell-therapy-manufacturer-to-reorghttps://www.live-feeds.com/feed/bristol-myers-ends-deal-with-cellares-cell-therapy-manufacturer-to-reorg#u49384Thu, 27 Aug 2026 00:56:21 +0000Bristol Myers Squibb ended its partnership with cell therapy manufacturer Cellares, leading the biotech startup to reorganize and lay off 100 employees. The termination follows production setbacks involving Cellares' automated platform used to manufacture an approved CAR-T cell therapy for blood cancer. Cellares leadership intends to resize the company after losing this large customer. The loss of the agreement has forced the fast-growing startup to reduce its workforce to align with its current operational scale.Why it mattersCAR-T therapies are complex blood cancer treatments that requi